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Purpose: The aim of the study was to compare the efficacy 
of parecoxib for postoperative analgesia after endoscopic 
turbinate and sinus surgery with the prodrug of acetaminophen, 
proparacetamol. Materials and Methods: Fifty American Society 
of Anesthesiology (ASA) physical status I-II patients, receiving 
functional endoscopic sinus surgery (FESS) and endoscopic 
turbinectomy, were investigated in a prospective, randomized, 
double-blind manner. After local infiltration with 1% 
mepivacaine, patients were randomly allocated to receive 
intravenous (IV) administration of either 40 mg of parecoxib (n
= 25) or 2 g of proparacetamol (n = 25) 15 min before 
discontinuation of total IV anaesthesia with propofol and 
remifentanil. A blinded observer recorded the incidence and 
severity of pain at admission to the post anaesthesia care unit 
(PACU) at 10, 20, and 30 min after PACU admission, and every 
1 h thereafter for the first 6 postoperative h. Results: The area 
under the curve of VAS (AUCVAS) calculated during the study 
period was 669 (28 - 1901) cm‧min in the proparacetamol group 
and 635 (26 - 1413) cm‧min in the parecoxib group (p = 0.34). 
Rescue morphine analgesia was required by 14 patients (56%) 
in the proparacetamol group and 12 patients (48%) in the 
parecoxib (p ≥0.05), while mean morphine consumption was 
5 - 3.5 mg and 5 - 2.0 mg in the proparacetamol groups and 
parecoxib, respectively (p ≥0.05). No differences in the 
incidence of side effects were recorded between the 2 groups. 
Patient satisfaction was similarly high in both groups, and all 
patients were uneventfully discharged 24 h after surgery. 
Conclusion:  In patients undergoing endoscopic nasal surgery, 
prior infiltration with local anaesthetics, parecoxib administered 
before discontinuing general anaesthetic, is not superior to 
proparacetamol in treating early postoperative pain.
Key Words: Postoperative pain, parecoxib, proparacetamol, 
analgesia, nasal surgery
INTRODUCTION
Functional endoscopic sinus surgery (FESS) and 
endoscopic turbinectomy have been developed in 
recent years in order to minimize surgical 
invasiveness.
1,2 These procedures are assumed to 
be more comfortable and less painful to patients; 
nonetheless, they are somehow associated with 
mild to moderate postoperative pain, which is 
related to both surgical trauma and nasal packing.
3
When the expected postoperative pain ranges 
from mild to moderate, routine analgesic treatment 
is usually based on non-opioid analgesics with 
rescue opioids.
4 However, the optimal analgesic 
regimen after endoscopic nasal surgery has not 
been wholly accepted and an opioid-oriented 
treatment is still often used.
5
Acetaminophen is an effective and safe non- 
opioid analgesic used to relieve mild to moderate 
pain. It is poorly soluble and unstable in aqueous 
solution, however its prodrug, proparacetamol, is 
water-soluble and can be administered intra-
venously for the treatment of postoperative pain. 
In the blood, proparacetamol is rapidly and 
completely converted by plasma esterase into 50% 
paracetamol.
6
Parecoxib is a water-soluble prodrug which 
undergoes complete and rapid biotransformation 
to valdecoxib, a potent selective inhibitor of Yigal Leykin, et al. 384
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cyclooxygenase-2 (anti-COX-2 agent).
7,8 The COX- 
2 inhibitors offer the advantage of less gastric 
toxicity and bleeding complications than traditional 
nonsteroidal anti-inflammatory drugs (NSAIDs).
9 
Studies on oral administration of rofecoxib (COX- 
2 inhibitor) and the combination of hydrocodone/ 
acetaminophen after endoscopic ENT surgery 
have shown to be safe and effective postoperative 
analgesia,
5,10 but oral administration may limit the 
use of these agents in the early postoperative 
period. The parenteral formulations of valdecoxib 
and acetaminophen have never been compared 
after endoscopic nasal surgery. We, therefore, 
conducted this prospective, randomized, double- 
blinded study to compare the efficacy of parecoxib 
for early postoperative analgesia after endoscopic 
turbinate and sinus surgery with the efficacy of 
proparacetamol for the same postoperative pain. 
MATERIALS AND METHODS
With institutional ethics committee approval 
and patients’ written consent, 50 ASA physical 
status I-II patients, aged 18 - 65 years, undergoing 
FESS (uncinectomy, middle antrostomy, and 
further procedures like ethmoidectomy and 
sphenoid exploration when indicated) and 
turbinate surgery were prospectively enrolled. 
Patients unable to cooperate or had history of 
gastric bleeding, impaired liver (transaminases ≥ 
twice upper limit) and/or renal function 
(creatinine ≥ 2.0 mg/dL), history of drug or 
alcohol abuse, chronic pain requiring major 
analgesics, sedatives, or corticosteroids, prothro-
mbotic tendencies, and known allergy to NSAIDs 
or other drugs used in the study were excluded.
No premedication or prophylactic antiemetic 
drugs were given. All patients received total IV 
anaesthesia with propofol (2 mg/kg bolus IV, 
f o l l o w e d  b y  a  c o n t i n u o u s  i n f u s i o n  a t  4-6m g /  
kg/h) and remifentanil (infusion rate ranging 
between 0.1 and 0.25 μg/kg/min). Muscle relaxa-
tion with rocuronium (0.6 mg/kg) was given to 
facilitate tracheal intubation and mechanical 
ventilation. Standard monitoring was used 
including electrocardiography (lead II), heart rate, 
noninvasive arterial blood pressure, and pulse 
oximetry. The attending anaesthesiologist who 
managed intraoperative anaesthesia was blinded 
to patient grouping. The same 2 surgeons performed 
all surgical procedures. Preoperative surgical field 
infiltration with 100 mg of 1% mepivacaine and 
0.25 mg of epinephrine was performed by a surgeon. 
Fifteen min before stopping remifentanil infusion, 
patients were randomly allocated to receive either 
40 mg of parecoxib (group parecoxib, n = 25) or 2g 
of proparacetamol (group proparacetamol, n = 25) 
using a computer generated sequence of random 
numbers. Since treatment drugs have different 
presentations and mode of administration, a double- 
dummy design was applied. Proparacetamol was 
administered by slow infusion over 15 min 
whereas parecoxib was injected by rapid bolus. 
Each patient received both an active product and 
the placebo of the other product. The physicians 
preparing the placebo and the study drugs were 
not further involved in patient management. 
At the end of surgery, bilateral nasal packs 
(Merocel-hydroxylated polyvinyl acetate, Medtronic 
Xomed, Jacksonville, FL, USA) were placed in all 
patients. IV anaesthetics were then discontinued, 
the patients were extubated after recovery of 
adequate spontaneous ventilation, and transferred 
to the PACU. 
An independent blinded observer recorded the 
degree of pain at PACU admission and after 10, 
20, and 30 min, then at every h for the first 6 h 
after surgery. At the same time, hemodynamic 
variables and occurrence of untoward events were 
also recorded. The degree of pain was measured 
using a 10 cm visual analogue scale (VAS, where 
"0" is no pain, "10" the worst imaginable pain). In 
case of inadequate pain relief (VAS ≥ 4c m ) ,  r e s -
cue IV analgesia was given with 2 mg of boluses 
of morphine injected at 10-min intervals until ad-
equate pain relief, and morphine consumption 
during the first 6 h after surgery was recorded. 
After 6 h, patients meeting PACU discharge 
criteria were transferred to the surgical ward. Pain 
was evaluated by surgical nursing staff. Following 
the 6th postoperative h, rescue analgesia for VAS 
≥ 4 was no longer morphine but 2 g of pro-
paracetamol IV since this drug is the standard 
postoperative pain medication on ward for 
patients undergoing FESS and turbinates surgery. 
The intensity of pain reported at 12 and 24 h after 
surgery was also recorded by surgical nursing Early Postoperative Analgesia for Nasal Surgery 385
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Table 1. Anthropometric Parameters of Studied Patients
Group proparacetamol (n = 25) Group parecoxib (n = 25)
Age (yrs)   34 ± 12   32 ± 10
Gender (M/F)  19 / 6  18 / 7
Height (cm) 168 ± 9 175 ± 9
Weight (kg)   73 ± 12   74 ± 13
Surgical procedure
FESS 16 (64%) 15 (60%)
Turbinectomy  9 (36%) 10 (40%)
Results are presented as mean (± SD) or number (%).
staff, since it as is routine at our institution.
Patient satisfaction was evaluated at 24 h after 
surgery using a 4-point numeric verbal scale (1 = 
not satisfied; 2 = partially satisfied; 3 = satisfied; 4 
= extremely satisfied). Both on the day of surgery 
and at 24 h, a surgeon who was blinded to patient 
grouping evaluated the presence of excessive 
bleeding with a subjective scale based on clinical 
experience.
Statistical analysis
The hypothesis under test was that IV 
administration of parecoxib before completion of 
endoscopic ENT surgery might reduce the degree 
of pain compared to proparacetamol. To objectify 
the exposition to pain of patients, we calculated 
the AUCVAS. The AUC for pain was estimated 
using the trapezium method by multiplying the 
time interval between 2 VAS measurements by 
their average, and is reported as a summary 
measure with cm‧min as the units; we calculated 
the AUC for pain during the first 6 h (AUCVAS- 
6h) and 24 h after surgery (AUCVAS-24 h). 
To calculate the sample size required, we 
considered the results of previous studies that 
evaluated the degree of pain reported after 
endoscopic ENT surgery.
5,10 The main outcome 
variable was the AUCVAS-24 h. We considered a 
reduction in median AUCVAS- 2 4h  o f  8 0 0c m ‧min 
w i t h  a n  e f f e c t  s i z e  t o  s t a n d a r d  d e v i a t i o n  r a t i o  
(E/S) of 0.8 as clinically relevant. A total of 25 
patients per group were required to detect the 
designed difference in the AUCVAS, accepting a 
2-tailed  α error of 5% and β error of 20%.
11
Statistical analysis was based on an intention- 
to-treat analysis and performed using the 
program Systat 7.0 (SPSS Inc., Chicago, IL, USA). 
Gaussian distribution of collected data was first 
evaluated using the Kolmogorov-Smirnov test. 
Continuous variables were then analysed using 
student’s t-test or Mann-Whitney U-test as 
appropriate. Changes over time were also assessed 
using a 2-way non-parametric analysis for repeated 
measures. Fisher’s exact test and Sheffe’s test were 
also used for post hoc analysis. Categorical 
variables were analyzed using contingency table 
analysis and Fisher’s exact test. Data are presented 
as mean (± SD), median (range) and number 
(percentage) as appropriate. A p value ≤ 0.05 was 
considered significant.
RESULTS
No differences in demographic parameters 
(Table 1) as well as in intraoperative and post-
operative hemodynamic variables (data not 
presented) were observed between the 2 groups. 
No differences were reported between the 2 
groups in the median (range) AUCVAS calculated 
during the first 6 and 24 h, or in the proportion 
of patients requiring rescue morphine and total 
morphine consumption before PACU discharge, 
and need for rescue analgesia during the first 24 
h after surgery (Table 2). Fig. 1 shows mean VAS 
changes during the first 6 h after surgery in the 
2 groups.Yigal Leykin, et al. 386
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Table 2. Area Under the Curve of Pain, Need for Rescue Morphine and Morphine Consumption
Group proparacetamol
(n = 25)
Group parecoxib
(n = 25)
p value
AUCVAS-6 h (cm‧min) 669 (28 - 1901) 635 (26 - 1413) 0.47
AUCVAS-24 h (cm‧min)  3675 (1800 - 7560)  2860 (1260 - 5600) 0.17
Need for rescue morphine in PACU 14 (56%) 12 (48%) 0.99
Morphine consumption in PACU (mg) 5 ± 3.5 5 ± 2.0 0.89
Rescue analgesia from 6th to 24th h  3 (12%) 4 (16%) 0.99
Area under the curve of pain over time during the first 6 (AUCVAS-6 h) and 24 hours (AUCVAS-24 h), need for rescue morphine 
and morphine consumption before post anaesthesia care unit (PACU) discharge, and need for rescue analgesia after PACU 
discharge during the first day after surgery in patients receiving either proparacetamol (group Proparacetamol, n = 25) or parecoxib 
(group Parecoxib, n = 25) after endoscopic ENT surgery. Results are presented as mean (± SD) or median (range) based on normal 
distribution of data or number (%).
Table 3. Incidence of Adverse Events Reported during First 24 h After Surgery in Patients Receiving Proparacetamol 
or Parecoxib After Endoscopic ENT Surgery
Group proparacetamol (n = 25) Group parecoxib (n = 25)
PONV  3 (12%) 2 (8%)
Gastric pain 0 (0%) 0 (0%)
Minor bleeding 0 (0%) 2 (8%)
PONV, post operative nausea and vomit.
Results are presented as number (%).
Fig. 1. Mean postoperative VAS measured at PACU 
admission for the first 6 h. 
Table 3 shows the incidence of side effects 
recorded in the 2 groups. Side effects were not 
related to the need for rescue doses of morphine, 
and bleeding was controlled simply by changing 
nasal cavity packing without surgical revision.
Patient satisfaction was similarly high in both 
groups [4 (3 - 4) in group paracetamol and 4 (3 - 
4) in group precoxib (p = 0.99)], and all patients 
were discharged uneventfully 24 h after surgery. 
However, satisfaction of patients who did not 
require rescue analgesia during the first day after 
surgery (morphine during the first 6 h and 
proparacetamol thereafter) was significantly higher 
than that of patients who received supplementary 
analgesia [4 (4 - 4) vs 3 (3 - 4), respectively, (p < 
0.001)].
DISCUSSION
This study compared the analgesic efficacy and 
tolerability of COX-2 selective inhibitor parecoxib 
to proparacetamol for postoperative analgesia 
after endoscopic ENT surgery. The results of this 
prospective, randomized, double-blinded investi-
gation showed that the administration of 40 mg of 
parecoxib IV was not preferable to 2 g of 
proparacetamol IV in managing postoperative 
pain. The proportion of patients requiring rescue Early Postoperative Analgesia for Nasal Surgery 387
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morphine and total morphine consumption as 
well as the incidence of side effects did not differ 
between the 2 groups.
The degree of pain reported after endoscopic 
sinus surgery was of moderate intensity,
3,10 
nonetheless, routine use of local anaesthetic 
infiltration or topical bupivacaine packing is not 
sufficient for the treatment of postoperative pain 
after nasal surgery, requiring additional systemic 
analgesia to achieve an opioid-sparing effect.
3,12 
Friedman et al. reported no differences in 
postoperative pain after endoscopic sinus surgery 
between infiltration with long acting (bupivacaine) 
or short acting (lidocaine) local anaesthetics.
3 
Postoperative pain score and the need for 
systemic analgesics were similar between the 2 
groups. 
Pain after nasal and sinus surgery is usually 
maximal in the first few postoperative h.
3 During 
this time, oral opioids are commonly prescribed as 
analgesics for symptomatic relief, but these drugs 
are frequently associated with adverse effects such 
as sedation, nausea, vomiting, urinary retention, 
pruritus, and respiratory depression.
5 For this 
reason, commonly used protocols of postoperative 
analgesia are based on a multimodal approach 
including non-opioid analgesics in order to 
achieve an opioid-sparing effect with concomitant 
reduction of opioid-related side effects.
13 NSAIDs 
are the most commonly used non-opioid analgesics 
for such purposes.
13
Although parecoxib and proparacetamol belong 
to the same pharmacological family, they act by 
different mechanisms. The analgesic action of 
parecoxib results from the inhibition of the COX-2 
isoenzyme that plays an important role in the 
synthesis of prostaglandin E2 while propara-
cetamol only weakly inhibits of prostaglandine 
synthesis and minimizes the typical actions of 
NSAIDs such as antiplatelet activity and 
gastrotoxicity.
7,14 The efficacy of parecoxib in 
postoperative pain relief is still controversial. Ng 
et al.
15 reported that 40 mg of parecoxib IV is less 
effective than 30 mg of ketorolac IV in the first h 
after minor gynaecological laparoscopic surgery. 
On the contrary, Bikhazi et al.
16 reported that a 
single dose of 40 mg of parecoxib was as effective 
as 30 mg of ketorolac after open gynaecologic 
surgery while Papadima et al.
19 reported that 40 
mg of parecoxib and 8 mg of lornoxicam were 
equianalgesic in the management of pain after 
laparoscopic cholecystectomy.
17 Concerning pro-
paracetamol, Van Aken et al. showed a similar 
analgesic efficacy between single dose of 2 g of 
proparacetamol IV and 10 mg of morphine IM in 
controlling acute postoperative pain after dental 
surgery.
18 Peduto et al.
19 demonstrated a significant 
morphine sparing effect of proparacetamol after 
orthopaedic surgery while Varrassi et al.
20 and 
Zhou et al.
21 reported similar analgesic efficacy 
between proparacetamol and ketorolac after 
gynaecologic and orthopaedic surgery.
19-21
Parenteral formulations of valdecoxib and 
acetaminophen allow intraoperative administration 
with a short onset of action
6,7  while postoperative 
parenteral formulation of acetaminophen provides 
a significantly better and longer analgesic effect 
than the same dosage in oral form.
6
Little information is available in the current 
literature evaluating the comparative efficacy of 
parecoxib and proparacetamol. A recently 
published trial compared the effects of these 2 
drugs only after inguinal hernia repair.
22 The 
authors investigated the intensity of postoperative 
pain, morphine consumption, and patient satisfac-
tion after a single injection of 40 mg of parecoxib 
or 2 injections of 2 g of proparacetamol within the 
first 12 postoperative h. Total morphine con-
sumption did not differ between the 2 groups, 
and pain was slightly less intense in the parecoxib 
group at rest, but pain did not differ while 
coughing. The incidence of side effects was 
similar and patient satisfaction was higher in the 
parecoxib group, although at an increased cost.
22,23
In conclusion, this prospective, randomized, 
double blinded study showed that 40 mg of 
parecoxib administered IV before discontinuing 
general anaesthesia is not superior to 2 g of 
proparacetamol IV in covering early postoperative 
pain after endoscopic ENT surgery.
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